Table 2.

Comparison of overall survival benefits among patients with different etiologies of HCC who received anti-PD-1/ anti-PDL1 based therapy

Etiology	Study	OS hazard ratio (95% CI)	No of subjects ICI-based therapy/Control
Non-viral	IMbrave 150	0.91 (0.52–1.59)	100	53
	KEYNOTE-240	0.88 (0.64–1.21)	163	85
	CheckMate-459	0.95 (0.74–1.22)	168	168
	RATIONALE-301	0.78 (0.55–1.12)	82	80
	COSMIC-312	1.18 (0.78–1.79)	169	86
	LEAP-002	0.86 (0.66–1.13)	118	133
	Camrelizumab + rivoceranib, 2022	0.65 (0.36–1.20)	42	45
	HIMALAYA	0.74 (0.67–0.95)	161	166
HCV-HCC	IMbrave 150	0.43 (0.21–0.87)	72	36
	KEYNOTE-240	0.96 (0.48–1.92)	43	21
	CheckMate-459	0.71 (0.49–1.01)	87	86
	RATIONALE-301	0.64 (0.38–1.08)	46	39
	COSMIC-312	1.10 (0.72–1.68)	136	67
	LEAP-002	0.86 (0.60–1.24)	94	87
	Camrelizumab + rivoceranib, 2022	0.56 (0.22–1.45)	22	29
	HIMALAYA	1.06 (0.76–1.49)	110	104
HBV-HCC	IMbrave 150	0.51 (0.32–0.81)	164	76
	KEYNOTE-240	0.57 (0.35–0.93)	72	29
	CheckMate-459	0.77 (0.56–1.05)	116	117
	RATIONALE-301	0.91 (0.73–1.14)	214	213
	COSMIC-312	0.53 (0.33–0.87)	127	64
	LEAP-002	0.75 (0.58–0.97)	192	193
	Camrelizumab + rivoceranib, 2022	0.53 (0.41–0.68)	208	197
	HIMALAYA	0.64 (0.48–0.86)	122	119